Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic

Gregory H. Bird, Navid Madani, Alisa F. Perry, Amy M. Princiotto, Jeffrey G. Supko, Xiaoying He, Evripidis Gavathiotis, Joseph G. Sodroski, Loren D. Walensky

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

The pharmacologic utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability. For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability. To overcome the proteolytic shortcomings of long peptides as therapeutics, we examined the biophysical, biological, and pharmacologic impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor. We find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption. We determined that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall α-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple. Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta). Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.

Original languageEnglish (US)
Pages (from-to)14093-14098
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number32
DOIs
StatePublished - Aug 10 2010
Externally publishedYes

Fingerprint

Hydrocarbons
Peptides
Biological Availability
HIV-1
Therapeutics
Proteolysis
Salvage Therapy
Virus Diseases
Antiviral Agents
Peptide Hydrolases
Pharmacokinetics
Amino Acids
Pharmaceutical Preparations
enfuvirtide

Keywords

  • Alpha-helix
  • Fusion inhibitor
  • HIV-1
  • Protease resistance
  • Stapled peptide

ASJC Scopus subject areas

  • General

Cite this

Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. / Bird, Gregory H.; Madani, Navid; Perry, Alisa F.; Princiotto, Amy M.; Supko, Jeffrey G.; He, Xiaoying; Gavathiotis, Evripidis; Sodroski, Joseph G.; Walensky, Loren D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 32, 10.08.2010, p. 14093-14098.

Research output: Contribution to journalArticle

Bird, Gregory H. ; Madani, Navid ; Perry, Alisa F. ; Princiotto, Amy M. ; Supko, Jeffrey G. ; He, Xiaoying ; Gavathiotis, Evripidis ; Sodroski, Joseph G. ; Walensky, Loren D. / Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 32. pp. 14093-14098.
@article{c839b4a6dfe34292a7f3396df5aa997c,
title = "Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic",
abstract = "The pharmacologic utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability. For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability. To overcome the proteolytic shortcomings of long peptides as therapeutics, we examined the biophysical, biological, and pharmacologic impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor. We find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption. We determined that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall α-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple. Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta). Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.",
keywords = "Alpha-helix, Fusion inhibitor, HIV-1, Protease resistance, Stapled peptide",
author = "Bird, {Gregory H.} and Navid Madani and Perry, {Alisa F.} and Princiotto, {Amy M.} and Supko, {Jeffrey G.} and Xiaoying He and Evripidis Gavathiotis and Sodroski, {Joseph G.} and Walensky, {Loren D.}",
year = "2010",
month = "8",
day = "10",
doi = "10.1073/pnas.1002713107",
language = "English (US)",
volume = "107",
pages = "14093--14098",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "32",

}

TY - JOUR

T1 - Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic

AU - Bird, Gregory H.

AU - Madani, Navid

AU - Perry, Alisa F.

AU - Princiotto, Amy M.

AU - Supko, Jeffrey G.

AU - He, Xiaoying

AU - Gavathiotis, Evripidis

AU - Sodroski, Joseph G.

AU - Walensky, Loren D.

PY - 2010/8/10

Y1 - 2010/8/10

N2 - The pharmacologic utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability. For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability. To overcome the proteolytic shortcomings of long peptides as therapeutics, we examined the biophysical, biological, and pharmacologic impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor. We find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption. We determined that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall α-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple. Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta). Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.

AB - The pharmacologic utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability. For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability. To overcome the proteolytic shortcomings of long peptides as therapeutics, we examined the biophysical, biological, and pharmacologic impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor. We find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption. We determined that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall α-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple. Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta). Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.

KW - Alpha-helix

KW - Fusion inhibitor

KW - HIV-1

KW - Protease resistance

KW - Stapled peptide

UR - http://www.scopus.com/inward/record.url?scp=77956294635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956294635&partnerID=8YFLogxK

U2 - 10.1073/pnas.1002713107

DO - 10.1073/pnas.1002713107

M3 - Article

VL - 107

SP - 14093

EP - 14098

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 32

ER -